Fig. 3 | Signal Transduction and Targeted Therapy

Fig. 3

From: Efficacy, safety and exploratory analysis of neoadjuvant tislelizumab (a PD-1 inhibitor) plus nab-paclitaxel followed by epirubicin/cyclophosphamide for triple-negative breast cancer: a phase 2 TREND trial

Fig. 3

Gene expression profile before neoadjuvant therapy and predictive index of response. a The volcano plot of transcriptomic characteristics between pCR and non-pCR patients at baseline (pre-neoadjuvant), b–f Gene set enrichment analysis of the Hallmark TNF, T cell receptor and JAK-STAT signaling pathway, PD-L1/PD-1 checkpoint pathway in cancers and cytokine-cytokine receptor interaction, g Box plot of the predictive score between pCR and non-pCR patients in training cohort, h The ROC curve of the predictive model in training cohort, i Box plot of the predictive score between pCR and non-pCR patients in validation cohort, j The ROC curve of the predictive model in training cohort. pCR pathological complete response, TNF tumor necrosis factor, NES normalized enrichment score, JAK Janus Kinase, STAT signal transducer and activator of transcription, PD-L1 programmed cell death 1 ligand 1, PD-1 programmed cell death-1, AUC area under the curve, ROC curve receiver operating characteristic curve

Back to article page